Anbio advances POC testing with new FIA analyzer
The analyzer promises to provide a cost-effective, comprehensive, and reliable solution for rapid point-of-care testing
9 Apr 2024
Anbio Biotechnology (Anbio) is expanding into the European healthcare industry with its latest product, the AF-100 C, a compact fluorescent immunoassay analyzer designed to revolutionize point-of-care diagnostics. With over 70 assays, the AF-100 C promises to significantly enhance patient care and improve clinical outcomes.
Anbio has introduced its comprehensive 'Point of Care' product line to the European Union. This strategic initiative represents a significant milestone for Anbio, facilitating collaborations with EU distributors and healthcare institutions, and underscoring the company's dedication to furnishing the European healthcare sector with cutting-edge diagnostic innovations.
At the forefront of Anbio's entry into the EU market is the AF-100 C analyzer, an advanced, single-channel, portable, rechargeable compact fluorescent immunoassay (FIA) analyzer. Despite its small size, the AF-100 C offers high-throughput and is ideally suited for a range of clinical environments, ensuring that healthcare professionals can provide superior patient care with greater efficiency.
Utilizing reagents incorporating radio frequency identification (RFID) chip technology for heightened precision and stability at room temperature for as long as 24 months, Anbio is poised to address the demands of Europe's healthcare landscape. Anbio's FIA test portfolio, offering rapid results within three to 15 minutes, signifies a notable leap forward in diagnostic technology.